- Home
- IMPP vs OVID Comparison
IMPP vs OVID Comparison
Compare IMPP & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMPP | OVID |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | Greece | United States |
| Employees | N/A | 23 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.7M | 126.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | IMPP | OVID |
|---|---|---|
| Price | $3.79 | $1.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $5.50 | $3.50 |
| AVG Volume (30 Days) | 723.4K | ★ 1.6M |
| Earning Date | 02-12-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $136,071,654.00 | $6,610,000.00 |
| Revenue This Year | $7.55 | $1,077.56 |
| Revenue Next Year | $58.58 | N/A |
| P/E Ratio | $3.63 | ★ N/A |
| Revenue Growth | N/A | ★ 945.89 |
| 52 Week Low | $2.12 | $0.24 |
| 52 Week High | $6.57 | $2.01 |
Technical Indicators
Market Signals| Indicator | IMPP | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 37.73 | 55.23 |
| Support Level | $3.63 | $1.59 |
| Resistance Level | $3.88 | $1.88 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 56.86 | 76.61 |
Price Performance
Historical ComparisonAbout IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.